June 24, 2025 – In a landmark move to accelerate research and innovation, the Department of Pharmaceuticals (DoP), under the Ministry of Chemicals and Fertilizers, launched the Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) Scheme with a ₹5,000 crore budget.
This state-of-the-art online portal aims to transform India’s pharmaceutical and medical technology sectors by bridging the R&D investment gap, fostering cutting-edge innovation, and reinforcing India’s position as a global leader in healthcare solutions.
Key Highlights of the PRIP Scheme
✅ Budget Allocation:
₹4,250 crore for research projects
₹700 crore for strengthening research infrastructure
₹50 crore for startups & MSMEs
✅ Priority Areas for Funding:
New Chemical & Biological Entities
Complex Generics & Biosimilars
Precision Medicine (Gene & Stem Cell Therapies)
Medical Devices & Orphan Drugs
Antimicrobial Resistance (AMR) Solutions
✅ Funding Categories:
| Category | Funding Support | Eligibility |
|---|---|---|
| B I | Up to ₹125 Cr (35% of cost) | Large Pharma/MedTech firms |
| B II | Up to ₹100 Cr (35% of cost) | Mid-sized R&D entities |
| B III | Up to ₹1 Cr per project | Startups & MSMEs |
Why PRIP Matters for India’s Pharma & MedTech Growth
🔹 Boosts R&D Investment – India currently spends $3 billion on pharma R&D vs. $60 billion (US) & $20 billion (China).
🔹 Reduces Import Dependence – Cuts reliance on Chinese APIs & medical device imports.
🔹 Strengthens Global Competitiveness – Positions India as an innovation hub beyond generics.
🔹 Supports Startups & MSMEs – Encourages breakthroughs in drug discovery & MedTech.
Industry Reactions & Strategic Impact
💬 Sheetal Arora, CEO, Mankind Pharma:
*”PRIP is a game-changer for Indian pharma. With ₹5,000 crore funding, we’re set to lead in new drug development while ensuring affordable healthcare globally.”*
💡 Expected Outcomes:
₹17,000 crore in R&D investments by FY28
More patents & high-value drug discoveries
Stronger industry-academia collaboration
How to Apply for PRIP Funding?
📌 Eligible entities (Pharma companies, MedTech firms, startups, research institutions) can:
Register on the PRIP Portal (Check DoP website for updates)
Submit proposals under relevant categories (B I, B II, or B III)
Collaborate with research institutions for higher funding chances
⚠ Note: The portal may face initial access issues. For queries, email:
📧 support-prip@pharma-dept.gov.in
(Subject: [Company Name] – [Category] – PRIP EoI Query)
India’s Pharma & MedTech Vision: What’s Next?
🚀 PLI Schemes (₹15,000 Cr for pharma, ₹3,420 Cr for MedTech)
🏭 Bulk Drug Parks (₹3,000 Cr in Gujarat, HP, Andhra)
🔬 Strengthening Pharma Labs (SPI Scheme – ₹500 Cr)
With disbursals starting December 2025, PRIP is set to revolutionize India’s healthcare innovation landscape.
📢 Stay Updated: Follow the Department of Pharmaceuticals for the latest announcements!
Final Takeaway
The PRIP Scheme is India’s bold step towards becoming a global pharma-innovation leader. By empowering startups, MSMEs, and large firms with funding, infrastructure, and collaboration opportunities, India is set to reduce import reliance, boost R&D, and deliver cutting-edge healthcare solutions to the world.
🔗 Learn More: Department of Pharmaceuticals Official Website
